Oral peptide GLP-1 receptor agonist
Semaglutide 50 mg oral once daily (higher dose oral program)
SEMA_PO_50MG_QD
Related
- All doses pooled: Semaglutide tablet
- Semaglutide 14 mg oral once daily (original tablet)
- Semaglutide 20 mg tablet once daily
- Semaglutide 40 mg tablet once daily
- Semaglutide 3 mg oral once daily (original tablet)
- Semaglutide 7 mg oral once daily (original tablet)
- Semaglutide oral once daily (original tablet), flexible dose: 3, 7 or 14 mg adjusted by HbA1c and tolerability
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -5.95 (-10.59 to -1.30) | 0.71 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -13.47 (-17.07 to -9.72) | 0.90 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 14.90 (4.85 to 37.90) | 0.48 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 15.53 (4.81 to 40.80) | 0.73 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 18.00 (6.83 to 41.71) | 0.82 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 16.91 (6.70 to 45.45) | 0.80 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.10 (0.50 to 2.43) | 0.52 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.38 (2.88 to 6.65) | 0.38 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.23 (3.58 to 15.62) | 0.29 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.67 (0.92 to 3.01) | 0.57 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.96 (0.97 to 3.93) | 0.52 |